Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy looks to leave past behind after US settlement

This article was originally published in Scrip

Executive Summary

Ranbaxy's $500 million settlement towards an investigation by the US Department of Justice (DOJ) concerning data integrity and manufacturing processes at two of the firm's Indian sites is expected to help bring down the curtains on a long-running issue that has troubled Daiichi Sankyo since it acquired Ranbaxy in 2008, and which has been high on the list of investor concerns.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts